

Post-Naloxone Symptoms Among People Administered 8mg vs. 4mg Intranasal Naloxone—New York State (NYS), 2022-23

Data Brief—September 2023 (revised)

An 8 milligram (mg) intranasal naloxone formulation was approved by the United States (US) Food and Drug Administration (FDA) in 2021. This data brief provides the first comparisons of the average number of doses administered, prevalence of post-naloxone symptoms, hospital transport, and survival among aided individuals administered 8mg compared with 4mg naloxone using data from a pilot conducted by the New York State Department of Health (NYSDOH) in collaboration with Albany Medical College and New York State Police (NYSP).

Timeline: March 26, 2022 to August 16, 2023

Setting: NYS

Participants: NYSP (3 of 11 troops received 8mg, others continued to receive 4mg)

Number of Administrations: 8mg: 101 4mg: 253

The **average number of naloxone doses administered** by law enforcement (LE) responders **was the same regardless of formulation**. There were **no significant differences in hospital transportation or survival** between groups.

	Mean Doses Given	Transported to Hospital	Survived
8mg	1.58 doses	81.0%	99.0%
4mg	1.67 doses	73.4%	99.2%

People administered 8mg naloxone had **2.51 times the likelihood of experiencing opioid withdrawal symptoms including vomiting** compared with those administered 4mg naloxone.

Post-Naloxone Symptom	8mg Naloxone % (n)	4mg Naloxone % (n) (Reference)	Relative Risk (95% Confidence Interval)
Opioid withdrawal symptoms including vomiting	37.6% (38)	19.4% (49)	2.51 (1.51-4.18)*
Disorientation	66.3% (67)	58.5% (148)	1.40 (0.86-2.27)
Lethargy	52.5% (53)	43.5% (110)	1.44 (0.90-2.28)

* Statistical significance at the p<0.05 level.



Department of Health

AIDS Institute

Contact: publicsafetynaloxone@health.ny.gov

Website: www.health.ny.gov/overdose

Revised: September 11, 2023

Produced: The Office of Program Evaluation and Research